Acute Stroke Imaging in the Era of the DAWN, DEFUSE 3 and WAKE-UP Study
Findings

Horst Urbach1, Elias Kellner2 and Karl Egger1
1. Department of Neuroradiology, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; 2. Department of Medical Physics, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany

Most stroke centres perform multimodal computed tomography imaging in order to select patients with acute stroke for mechanical thrombectomy and/or intravenous (IV) thrombolysis. After the DAWN (Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3) studies, the time window for the treatment of stroke has been extended from 6 hours to 24 hours provided that a small infarct core and significant tissue at risk is documented. After the WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke) study, wake-up strokes can be selected for IV thrombolysis if diffusion-weighted imaging is positive and fluid-attenuated inversion recovery magnetic resonance imaging is negative. We propose an imaging algorithm in which the imaging modality is mainly selected with respect to the National Institutes of Health Stroke Scale.

In 2018, two randomised controlled trials, DAWN (the Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3), implemented computed tomography (CT) and magnetic resonance imaging (MRI) in patients with stroke.1,2 These studies showed the benefit of mechanical thrombectomy in patients with large vessel occlusions (LVO) presenting within 6–24 hours after symptom onset and having substantial tissue at risk.1,2 Another MRI-based randomised controlled trial, WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke), showed the benefit of intravenous (IV) thrombolysis in patients with wake-up stroke.3-5 Do these study findings mean that a patient with LVO or wake-up stroke must be studied with MRI? Additionally, how does that concur with the fact that >95% of stroke centres perform multimodal CT imaging in patients with acute stroke? Must these stroke centres now provide both CT and MRI capacities to investigate stroke patients? In order to answer these questions, it is necessary to take a closer look at the rationale and the results of these studies with the aim of devising an imaging algorithm.

Rationale of the extended mechanical thrombectomy studies DAWN and DEFUSE 3

The concept of the DAWN and DEFUSE 3 studies was to acquire magnetic resonance angiography or CT angiography (CTA) to prove the presence of LVO, to acquire MRI diffusion-weighted imaging (DWI) or CT perfusion (CTP) to depict the infarct core, and to acquire MRI perfusion-weighted imaging (PWI) or CTP to depict the tissue at risk.2 In DEFUSE 3, patients with occlusion of the internal carotid artery or occlusion of the first segment of the middle cerebral artery (M1) and a so-called target mismatch profile (ischaemic core volume <70 mL, mismatch ratio >1.8 and mismatch volume >15 mL) were included. The infarct core was defined as tissue with a relative cerebral blood flow <30% compared with the contralateral hemisphere. This value was derived from the data of 103 patients, in which DWI-MRI was acquired in a mean of 36 minutes after CTP.2 Using this measure, the infarct core is not overestimated and smaller than on DWI.6

The tissue at risk in DAWN and DEFUSE 3 was defined as having a time to maximum of the residue function (Tmax) prolongation >6 seconds. Mismatch volume (tissue at risk – infarct core volumes) was determined in real-time with specific automated software (RAPID software, SchemaView, Inc., Menlo Park, California, USA).1,3 This software is only available in some stroke centres in Europe, and although other software tools have achieved CE approval in the meantime, many stroke specialists treat patients within the 6–24-hour window as they would those within the 6-hour window. It means they do not consider CT or MRI perfusion but base their decision on the ASPECTS score. The infarct cores – tissue at risk maps presented in Figures 1–4 were calculated with the mRay-VEOcore software tool (www.veobrain.com).
Acute Stroke Imaging in the Era of the DAWN, DEFUSE 3 and WAKE-UP Study Findings

Rationale of the WAKE-UP study

If a patient wakes up with a stroke the time of onset cannot be determined. In the WAKE-UP study, this onset was estimated via DWI and fluid-attenuated inversion recovery (FLAIR) MRI. An infarct which is clearly visible on FLAIR is likely to be older than 4.5 hours and those patients are not considered suitable for IV thrombolysis. However, it is difficult to define what one might consider a clearly FLAIR-visible infarct. This has been shown in a post-hoc analysis in which 5% of patients treated with IV thrombolysis were considered to have a FLAIR-visible infarct (Figure 1).1

Summary of the main results of DAWN, DEFUSE 3, WAKE-UP and other studies

The results of these key clinical studies are illuminating but difficult to incorporate into one imaging concept. The DAWN and DEFUSE 3 studies showed that thrombectomy for acute/ischaemic stroke, given with standard care to patients within 6–24 hours or 6–16 hours of onset, had better disability/functional outcomes at 90 days than patients who received standard care alone1,2 (outcomes of key trials are summarised in Table 1). The WAKE-UP study showed that in patients with acute stroke of unknown time of onset, treatment with IV thrombolysis, which was guided by a mismatch between DWI and FLAIR in the brain region of the ischaemia, resulted in better functional outcomes but more intracranial haemorrhages than placebo at 90 days.3 The WAKE-UP study, however, also showed that the 36% of patients with National Institutes of Health Stroke Scale (NIHSS) 0–4 did not benefit from IV thrombolysis.4 In a retrospective analysis of databases, patients with a NIHSS between 5–10 showed benefit from IV thrombolysis, but also from mechanical thrombectomy if they had an LVO.5 Patients with a NIHSS >10 have a high probability (>65%) of having an LVO and require DWI/PWI or CTP in order to prove that they have a small infarct core and substantial tissue at risk.6 The use of the NIHSS, however, is debated, and the cortical symptoms of neglect, aphasia alone or combined with motor symptoms, are more reliable indicators of an LVO than the NIHSS.7

Proposal of an imaging algorithm

If the NIHSS is to be used for selecting imaging modalities we propose the following imaging algorithm irrespective of the time window:

**NIHSS 0–5**: Unenhanced CT 2 hours after symptom onset; (B and C) CTP with the tissue at risk superimposed in yellow (B), note that the red tissue is confined to the white matter and shows that collateralisation is worse than in the grey matter; (D) The thromboembolic occlusion was overlooked on CTA; (E) cerebral blood flow map; (F) Tmax map.

CT = computed tomography; CTA = computed tomography angiography; CTP = computed tomography perfusion; NIHSS: National Institutes of Health Stroke Scale; Tmax = time to maximum of the residue function.

**Table 1**: Outcome of randomised controlled trials of mechanical thrombectomy with stent-retrievers versus best medical therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>MT+BMM: mRS 0–2</th>
<th>BMM: mRS 0–2</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR CLEAN7</td>
<td>76/233 (33%)</td>
<td>51/267 (19%)</td>
<td>2.05 (1.36–3.09)</td>
</tr>
<tr>
<td>EXTEND IA8</td>
<td>25/35 (71%)</td>
<td>14/35 (40%)</td>
<td>3.75 (1.78–10.17)</td>
</tr>
<tr>
<td>ESCAPE22</td>
<td>87/164 (53%)</td>
<td>43/147 (29%)</td>
<td>2.73 (1.71–4.37)</td>
</tr>
<tr>
<td>SWIFT PRIME9</td>
<td>45/103 (44%)</td>
<td>29/103 (28%)</td>
<td>2.75 (1.53–4.94)</td>
</tr>
<tr>
<td>REVASCAT10</td>
<td>59/98 (60%)</td>
<td>33/93 (35%)</td>
<td>1.98 (1.11–1.53)</td>
</tr>
<tr>
<td>THRACT11</td>
<td>106/200 (53%)</td>
<td>85/202 (42%)</td>
<td>1.55 (1.05–2.30)</td>
</tr>
<tr>
<td>THERAPY12</td>
<td>19/50 (38%)</td>
<td>14/46 (30%)</td>
<td>1.40 (0.60–3.27)</td>
</tr>
<tr>
<td>PISTE13</td>
<td>17/33 (52%)</td>
<td>12/30 (40%)</td>
<td>1.53 (0.58–4.01)</td>
</tr>
<tr>
<td>EAS14</td>
<td>19/35 (54%)</td>
<td>14/32 (44%)</td>
<td>2.03 (1.68–2.46)</td>
</tr>
<tr>
<td>DAWN15</td>
<td>52/107 (49%)</td>
<td>13/99 (13%)</td>
<td>2.10 (1.10–3.00)*</td>
</tr>
<tr>
<td>DEFUSE 316</td>
<td>41/92 (45%)</td>
<td>15/90 (17%)</td>
<td>2.67 (1.60–4.48)</td>
</tr>
</tbody>
</table>

*Good outcome had been defined as mRS of 0–2.

**Figure 1**: Diffusion-weighted imaging and perfusion magnetic resonance imaging of a patient with stroke and no mismatch

(A) Diffusion-weighted imaging with superimposed infarct core in red and tissue at risk in yellow; (B) Although the infarct is (clearly) visible on FLAIR MRI, the patient was treated with IV thrombolysis; (C) Follow-up CT after 1 day shows the infarct extension identical to the area in A; (D) ADC map; (E) Tmax map; (F) cerebral blood flow map.

ADC = apparent diffusion coefficient; CT = computed tomography; CTA = computed tomography angiography; CTP = computed tomography perfusion; FLAIR MRI = fluid-attenuated inversion recovery magnetic resonance imaging; IV = intravenous; Tmax = time to maximum of the residue function.

**Figure 2**: Distal left-sided anterior cerebral artery occlusion in an 82-year-old woman with hemiparesis, aphasia and neglect (NIHSS 9)

(A) Unenhanced CT 2 hours after symptom onset; (B) CTP with the tissue at risk superimposed in yellow (B), note that the red tissue is confined to the white matter and shows that collateralisation is worse than in the grey matter; (D) The thromboembolic occlusion was overlooked on CTA; (E) cerebral blood flow map; (F) Tmax map.

CT = computed tomography; CTA = computed tomography angiography; CTP = computed tomography perfusion; NIHSS: National Institutes of Health Stroke Scale; Tmax = time to maximum of the residue function.

(A) Unenhanced CT 2 hours after symptom onset; (B) CTP with the tissue at risk superimposed in yellow (B), note that the red tissue is confined to the white matter and shows that collateralisation is worse than in the grey matter; (D) The thromboembolic occlusion was overlooked on CTA; (E) cerebral blood flow map; (F) Tmax map.

ADC = apparent diffusion coefficient; CT = computed tomography; CTA = computed tomography angiography; CTP = computed tomography perfusion; FLAIR MRI = fluid-attenuated inversion recovery magnetic resonance imaging; IV = intravenous; Tmax = time to maximum of the residue function.

**Table 1**: Outcome of randomised controlled trials of mechanical thrombectomy with stent-retrievers versus best medical therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>MT+BMM: mRS 0–2</th>
<th>BMM: mRS 0–2</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MR CLEAN7</td>
<td>76/233 (33%)</td>
<td>51/267 (19%)</td>
<td>2.05 (1.36–3.09)</td>
</tr>
<tr>
<td>EXTEND IA8</td>
<td>25/35 (71%)</td>
<td>14/35 (40%)</td>
<td>3.75 (1.78–10.17)</td>
</tr>
<tr>
<td>ESCAPE22</td>
<td>87/164 (53%)</td>
<td>43/147 (29%)</td>
<td>2.73 (1.71–4.37)</td>
</tr>
<tr>
<td>SWIFT PRIME9</td>
<td>45/103 (44%)</td>
<td>29/103 (28%)</td>
<td>2.75 (1.53–4.94)</td>
</tr>
<tr>
<td>REVASCAT10</td>
<td>59/98 (60%)</td>
<td>33/93 (35%)</td>
<td>1.98 (1.11–1.53)</td>
</tr>
<tr>
<td>THRACT11</td>
<td>106/200 (53%)</td>
<td>85/202 (42%)</td>
<td>1.55 (1.05–2.30)</td>
</tr>
<tr>
<td>THERAPY12</td>
<td>19/50 (38%)</td>
<td>14/46 (30%)</td>
<td>1.40 (0.60–3.27)</td>
</tr>
<tr>
<td>PISTE13</td>
<td>17/33 (52%)</td>
<td>12/30 (40%)</td>
<td>1.53 (0.58–4.01)</td>
</tr>
<tr>
<td>EAS14</td>
<td>19/35 (54%)</td>
<td>14/32 (44%)</td>
<td>2.03 (1.68–2.46)</td>
</tr>
<tr>
<td>DAWN15</td>
<td>52/107 (49%)</td>
<td>13/99 (13%)</td>
<td>2.10 (1.10–3.00)*</td>
</tr>
<tr>
<td>DEFUSE 316</td>
<td>41/92 (45%)</td>
<td>15/90 (17%)</td>
<td>2.67 (1.60–4.48)</td>
</tr>
</tbody>
</table>

*Good outcome had been defined as mRS of 0–2.

BMM = best medical therapy; CI = confidence interval; mRS = modified Rankin score; MT = mechanical thrombectomy; OR = odds ratio.
Special Report  Stroke

Figure 3: A 67-year-old woman with a thromboembolic middle cerebral artery M1 segment occlusion due to atrial fibrillation (NIHSS 14)

(A) CTP after 60 minutes shows tissue at risk of the cortical MCA territory; (C) thromboembolic MCA M1 segment occlusion due to atrial fibrillation. (G) The MCA was recanalised with three retrieval manoeuvres (Solitaire 6x40); (H) Follow-up CT at day 1 shows a small new cortical MCA infarct (open arrow) while the discrete hypodensity of the right lentiform nucleus was already visible on the initial CT (B, D, H, arrows). CT = computed tomography; CTP = computed tomography perfusion; MCA = middle cerebral artery; NIHSS = National Institutes of Health Stroke Scale.

NIHSS 5–10: DWI/PWI or CT (CT/CTA/CTP) can be used interchangeably. Speed (“time is brain”) and display of the LVO and the arterial access via the aortic arch are in favour of CTA/CTP. CTP better shows peripheral infeasible in whom are likely to be missed with CTA alone (Figure 2). It also better illustrates the tissue at risk volume in patients with M2 occlusions.

NIHSS >10: Patients have a high likelihood of LVO and the need of mechanical thrombectomy. Speed, patient compliance, and display of LVO and arterial access via the aortic arch are in clear favour of CTA/CTP (Figures 3 and 4).

Current guidelines of the American Heart Association and the European Stroke Organisation – European Society of Minimally Invasive Neurological Therapy (ESO-ESMINT) do not recommend CTP or PWI within the first 6 hours following stroke onset. The rationale for this is that in a small subgroup of patients studied with >70 mL infarct volume on CTP, two of 25 (8%) compared with none of 25 control patients achieved functional independence. We respect these recommendations and would rather treat a patient than excluding them. Those who would benefit and those who would not need to be determined at an early stage. If these data are not acquired in the 6–12-hour window an opportunity is lost and it is not possible to understand subsequent changes in the brain tissue.

It is difficult to predict the functional outcome following successful recanalisation in an individual patient. This is because brain tissue dies at variable speeds in different patients. The following percentages may be used for outcome estimation provided that complete recanalisation is achieved. Less than 10% of patients with M1 or carotid T-occlusions already have large ischaemic core volumes (>80 mL) at their initial DWI examination within 3 hours. Patients with large ischaemic cores typically have a worse outcome than those with small ischaemic cores. The infarct core volume is reliably assessed with CTP but not with visual or eASPECTS analysis of unenhanced CT scans. The final infarct volume is strongly associated with the functional outcome.

Around 20% of patients have large and severely hypoperfused tissue at risk (Tmax prolongation >10 seconds and mismatch volume >100 mL = malignant imaging profile) with fast infarct growth rates from about 15 mL/h to as high as 100 mL/h. The vast majority of patients likely (>70%) fall into a category in which there is little or no infarct growth within the first day or the infarct core grows with a low rate of 3–10 mL/h. Patients clearly benefit from mechanical thrombectomy within the first 24 hours or even longer. The net benefit of this treatment compared with IV thrombolysis or supportive therapy (after 4.5 hours) is even larger in the late time window.

In summary, an ideal imaging algorithm should consider the clinical deficit and, if known, the interval between onset of symptoms and imaging. In this context, multimodal acute stroke CT imaging can be used to indicate the suitability of mechanical thrombectomy and/or IV thrombolysis. Multimodal acute stroke CT imaging likely predicts the patient’s outcome following recanalisation therapy better than the time interval between symptom onset and therapy.


